AMGEN INC (1AMGN.MI) Stock Fundamental Analysis
Europe - BIT:1AMGN - US0311621009 - Common Stock
293.45 EUR
+36.9 (+14.38%)
Taking everything into account, 1AMGN scores 5 out of 10 in our fundamental rating. 1AMGN was compared to 74 industry peers in the Biotechnology industry. While 1AMGN belongs to the best of the industry regarding profitability, there are concerns on its financial health. 1AMGN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1AMGN was profitable.
1AMGN had a positive operating cash flow in the past year.
In the past 5 years 1AMGN has always been profitable.
Each year in the past 5 years 1AMGN had a positive operating cash flow.
1.2 Ratios
1AMGN has a better Return On Assets (7.53%) than 85.33% of its industry peers.
Looking at the Return On Equity, with a value of 89.11%, 1AMGN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
1AMGN's Return On Invested Capital of 14.12% is amongst the best of the industry. 1AMGN outperforms 90.67% of its industry peers.
1AMGN had an Average Return On Invested Capital over the past 3 years of 13.04%. This is in line with the industry average of 12.80%.
The last Return On Invested Capital (14.12%) for 1AMGN is above the 3 year average (13.04%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.53% | ||
| ROE | 89.11% | ||
| ROIC | 14.12% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
1.3 Margins
1AMGN has a better Profit Margin (18.96%) than 86.67% of its industry peers.
1AMGN's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 31.30%, 1AMGN belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
In the last couple of years the Operating Margin of 1AMGN has declined.
1AMGN has a better Gross Margin (69.71%) than 65.33% of its industry peers.
1AMGN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.3% | ||
| PM (TTM) | 18.96% | ||
| GM | 69.71% |
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1AMGN is still creating some value.
Compared to 1 year ago, 1AMGN has more shares outstanding
1AMGN has less shares outstanding than it did 5 years ago.
1AMGN has a better debt/assets ratio than last year.
2.2 Solvency
The Debt to FCF ratio of 1AMGN is 4.94, which is a neutral value as it means it would take 1AMGN, 4.94 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 1AMGN (4.94) is better than 81.33% of its industry peers.
A Debt/Equity ratio of 7.24 is on the high side and indicates that 1AMGN has dependencies on debt financing.
1AMGN has a worse Debt to Equity ratio (7.24) than 68.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.24 | ||
| Debt/FCF | 4.94 | ||
| Altman-Z | N/A |
ROIC/WACC1.5
WACC9.43%
2.3 Liquidity
1AMGN has a Current Ratio of 1.31. This is a normal value and indicates that 1AMGN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.31, 1AMGN is doing worse than 66.67% of the companies in the same industry.
1AMGN has a Quick Ratio of 1.31. This is a bad value and indicates that 1AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
1AMGN's Quick ratio of 0.98 is on the low side compared to the rest of the industry. 1AMGN is outperformed by 69.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
1AMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.26%, which is quite good.
The Earnings Per Share has been growing slightly by 5.97% on average over the past years.
1AMGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.88%.
The Revenue has been growing slightly by 7.43% on average over the past years.
EPS 1Y (TTM)17.26%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%21.13%
Revenue 1Y (TTM)12.88%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%9.43%
3.2 Future
Based on estimates for the next years, 1AMGN will show a small growth in Earnings Per Share. The EPS will grow by 4.13% on average per year.
1AMGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.12% yearly.
EPS Next Y8.45%
EPS Next 2Y5.44%
EPS Next 3Y4.87%
EPS Next 5Y4.13%
Revenue Next Year7.54%
Revenue Next 2Y4.58%
Revenue Next 3Y3.91%
Revenue Next 5Y3.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 15.57, the valuation of 1AMGN can be described as correct.
Based on the Price/Earnings ratio, 1AMGN is valued cheaply inside the industry as 89.33% of the companies are valued more expensively.
1AMGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.91.
With a Price/Forward Earnings ratio of 15.40, 1AMGN is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1AMGN indicates a rather cheap valuation: 1AMGN is cheaper than 93.33% of the companies listed in the same industry.
1AMGN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.57.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.57 | ||
| Fwd PE | 15.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1AMGN is valued cheaper than 82.67% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1AMGN indicates a rather cheap valuation: 1AMGN is cheaper than 90.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.05 | ||
| EV/EBITDA | 12.48 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1AMGN does not grow enough to justify the current Price/Earnings ratio.
1AMGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.84
PEG (5Y)2.61
EPS Next 2Y5.44%
EPS Next 3Y4.87%
5. Dividend
5.1 Amount
1AMGN has a Yearly Dividend Yield of 3.22%.
1AMGN's Dividend Yield is rather good when compared to the industry average which is at 11.17. 1AMGN pays more dividend than 97.33% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, 1AMGN pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.22% |
5.2 History
On average, the dividend of 1AMGN grows each year by 9.41%, which is quite nice.
Dividend Growth(5Y)9.41%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
36.49% of the earnings are spent on dividend by 1AMGN. This is a low number and sustainable payout ratio.
The dividend of 1AMGN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP36.49%
EPS Next 2Y5.44%
EPS Next 3Y4.87%
BIT:1AMGN (11/12/2025, 7:00:00 PM)
293.45
+36.9 (+14.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.15%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap157.98B
Revenue(TTM)34.92B
Net Income(TTM)6.62B
Analysts72
Price Target274.32 (-6.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.22% |
Yearly Dividend7.79
Dividend Growth(5Y)9.41%
DP36.49%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.69%
Min EPS beat(2)11.64%
Max EPS beat(2)11.73%
EPS beat(4)4
Avg EPS beat(4)8.21%
Min EPS beat(4)2.49%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)4.35%
EPS beat(12)10
Avg EPS beat(12)3.9%
EPS beat(16)14
Avg EPS beat(16)4.02%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)0.68%
Revenue beat(4)2
Avg Revenue beat(4)-0.49%
Min Revenue beat(4)-2.15%
Max Revenue beat(4)0.68%
Revenue beat(8)2
Avg Revenue beat(8)-1.11%
Revenue beat(12)3
Avg Revenue beat(12)-0.9%
Revenue beat(16)4
Avg Revenue beat(16)-0.92%
PT rev (1m)-2.09%
PT rev (3m)-2.09%
EPS NQ rev (1m)-6.26%
EPS NQ rev (3m)-6.26%
EPS NY rev (1m)1.2%
EPS NY rev (3m)1.2%
Revenue NQ rev (1m)0.71%
Revenue NQ rev (3m)0.71%
Revenue NY rev (1m)1.12%
Revenue NY rev (3m)1.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.57 | ||
| Fwd PE | 15.4 | ||
| P/S | 5.23 | ||
| P/FCF | 16.05 | ||
| P/OCF | 15.21 | ||
| P/B | 24.6 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.48 |
EPS(TTM)18.85
EY6.42%
EPS(NY)19.05
Fwd EY6.49%
FCF(TTM)18.28
FCFY6.23%
OCF(TTM)19.29
OCFY6.57%
SpS56.07
BVpS11.93
TBVpS-57.58
PEG (NY)1.84
PEG (5Y)2.61
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.53% | ||
| ROE | 89.11% | ||
| ROCE | 16.21% | ||
| ROIC | 14.12% | ||
| ROICexc | 16.03% | ||
| ROICexgc | 59.12% | ||
| OM | 31.3% | ||
| PM (TTM) | 18.96% | ||
| GM | 69.71% | ||
| FCFM | 32.61% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexgc growth 3Y3.26%
ROICexgc growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score8
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.24 | ||
| Debt/FCF | 4.94 | ||
| Debt/EBITDA | 3.25 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.72% | ||
| Profit Quality | 172.01% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | N/A |
F-Score8
WACC9.43%
ROIC/WACC1.5
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)17.26%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%21.13%
EPS Next Y8.45%
EPS Next 2Y5.44%
EPS Next 3Y4.87%
EPS Next 5Y4.13%
Revenue 1Y (TTM)12.88%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%9.43%
Revenue Next Year7.54%
Revenue Next 2Y4.58%
Revenue Next 3Y3.91%
Revenue Next 5Y3.12%
EBIT growth 1Y75.18%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year39.98%
EBIT Next 3Y10.33%
EBIT Next 5Y5.65%
FCF growth 1Y17.55%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y11.23%
OCF growth 3Y7.45%
OCF growth 5Y4.66%
AMGEN INC / 1AMGN.MI FAQ
Can you provide the ChartMill fundamental rating for AMGEN INC?
ChartMill assigns a fundamental rating of 5 / 10 to 1AMGN.MI.
Can you provide the valuation status for AMGEN INC?
ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (1AMGN.MI). This can be considered as Fairly Valued.
How profitable is AMGEN INC (1AMGN.MI) stock?
AMGEN INC (1AMGN.MI) has a profitability rating of 7 / 10.
What is the valuation of AMGEN INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for AMGEN INC (1AMGN.MI) is 15.57 and the Price/Book (PB) ratio is 24.6.
What is the financial health of AMGEN INC (1AMGN.MI) stock?
The financial health rating of AMGEN INC (1AMGN.MI) is 3 / 10.